Human Lung Cancer Tissue Lysates
Pricing |
Normal Lysates: $125/100 ug |
Tumor Lysates: $175/100 ug |
Nor./Tum. set: $270.00 (10% off) |
Discounts |
2-8 Vials 10% |
9-20 Vials 15% |
>20 Vials 20% |
Introduction:
LUNG NSCLC:
Non-small cell lung cancer can be classified based on their cellular origins and further divided into a number of subtypes according to The New World Health Organization/International Association for the Study of Lung Cancer. Histologic Classification of Non-Small Cell Lung Carcinomas. These include:
Squamous cell carcinoma - Papillary, Clear cell, Small cell, Basaloid.
Adenocarcinoma - Acinar, Papillary, Bronchioloalveolar carcinoma (Nonmucinous, Mucinous, Mixed mucinous and nonmucinous or indeterminate cell type), Solid adenocarcinoma with mucin, Adenocarcinoma with mixed subtypes, Variants (Well-differentiated fetal adenocarcinoma, Mucinous (colloid) adenocarcinoma, Mucinous cystadenocarcinoma, Signet ring adenocarcinoma, Clear cell adenocarcinoma).
Large cell carcinoma - Variants (Large-cell neuroendocrine carcinoma, Combined large-cell neuroendocrine carcinoma, Basaloid carcinoma, Lymphoepithelioma-like carcinoma, Clear cell carcinoma, Large-cell carcinoma with rhabdoid phenotype).
Adenosquamous carcinoma.
Carcinomas with pleomorphic, sarcomatoid or sarcomatous elements - Carcinomas with spindle and/or giant cells, Spindle cell carcinoma, Giant cell carcinoma, Carcinosarcoma, Pulmonary blastoma.
Carcinoid tumor - Typical carcinoid, Atypical carcinoid. Carcinomas of salivary-gland type - Mucoepidermoid carcinoma, Adenoid cystic carcinoma, Others.
Unclassified carcinoma.
LUNG SCLC:
The current classification of subtypes of small cell lung cancer is:
Small cell carcinoma. Mixed small cell/large cell carcinoma.
Combined small cell carcinoma (i.e., small cell lung cancer combined with neoplastic squamous and/or glandular components).
Human Lung Cancer Tissue Lysates | ||||||
Catalog Number |
Diagnosis |
Grade |
Stage |
TNM |
Sex |
Age |
Papillary Adenocarcinoma |
2 |
IIIA |
T3N0M0 |
M |
42 |
|
Adenocarcinoma |
2 |
II |
T2N1M0 |
M |
73 |
|
Papillary Adenocarcinoma |
2 |
II |
T1N0M0 |
M |
50 |
|
Adenocarcinoma |
2 |
n/a |
n/a |
M |
74 |
|
Adenocarcinoma |
3 |
IB |
T2N0M0 |
M |
45 |
|
Papillary Adenocarcinoma |
2 |
I |
T1N0M0 |
M |
46 |
|
Adenocarcinoma |
2 |
I |
T1N0M0 |
M |
42 |
|
Adenocarcinoma |
2 |
I |
T1N0M0 |
M |
59 |
|
Papillary Adenocarcinoma |
2 |
IIIA |
T3N0M0 |
M |
63 |
|
Papillary Adenocarcinoma |
1 |
IIIA |
T3N0M0 |
M |
68 |
|
Adeno-Squamous Cell Carcinoma |
2 |
I |
T1N0M0 |
M |
72 |
|
Adeno-Squamous Cell Carcinoma |
2 |
I |
T2N0M0 |
M |
62 |
|
Adeno-Squamous Cell Carcinoma |
3 |
III |
T3NxM0 |
M |
68 |
|
Large Cell Carcinoma |
3 |
III |
T3NxM0 |
M |
26 |
|
Large Cell Carcinoma |
3 |
III |
T3N0Mx |
M |
70 |
|
Large Cell Carcinoma |
3 |
III |
n/a |
M |
55 |
|
Large Cell Carcinoma |
3 |
I |
T2N0M0 |
M |
68 |
|
Large Cell Carcinoma |
3 |
I |
n/a |
M |
61 |
|
Large Cell Carcinoma |
2 |
IIIA |
T3N0M0 |
M |
31 |
|
Large Cell Carcinoma |
3 |
II |
T2N0Mx |
M |
63 |
|
Large Cell Carcinoma |
3 |
III |
n/a |
M |
59 |
|
Large Cell Carcinoma |
3 |
III |
n/a |
M |
46 |
|
Large Cell Carcinoma |
1 |
I |
T2N0M0 |
M |
69 |
|
Small Cell Carcinoma |
3 |
IIB |
T2N1M0 |
M |
73 |
|
Adenocarcinoma |
2 |
n/a |
n/a |
F |
40 |
|
Squamous Cell Carcinoma |
2 |
IIIA |
T3N0M0 |
M |
50 |
|
Squamous Cell Carcinoma |
2 |
I |
T2N0M0 |
M |
45 |
|
Squamous Cell Carcinoma |
2 |
I |
T2N0M0 |
M |
51 |
|
Squamous Cell Carcinoma |
2 |
I |
T2N0M0 |
M |
74 |
|
Squamous Cell Carcinoma |
2 |
III |
T3N0M0 |
M |
69 |
|
Squamous Cell Carcinoma |
2 |
III |
T3N0M0 |
M |
55 |
|
Squamous Cell Carcinoma |
2 |
III |
T3N2M0 |
M |
73 |
|
Squamous Cell Carcinoma |
3 |
IIIA |
T3N0M0 |
M |
60 |
|
Squamous Cell Carcinoma |
3 |
n/a |
n/a |
M |
37 |
|
Squamous Cell Carcinoma |
3 |
III |
T3N0M0 |
M |
62 |
|
Squamous Cell Carcinoma |
2 |
I |
T1N0M0 |
M |
58 |
|
Squamous Cell Carcinoma |
2 |
II |
T2N0M0 |
M |
40 |
|
Squamous Cell Carcinoma |
2 |
I |
T1N0M0 |
M |
69 |
|
Squamous Cell Carcinoma |
2 |
I |
T1N0M0 |
M |
70 |
|
Squamous Cell Carcinoma |
2 |
I |
T2N0M0 |
M |
50 |
|
Adenocarcinoma |
n/a |
n/a |
T1N0M0 |
F |
67 |
|
Adenocarcinoma |
n/a |
I |
T1N0M0 |
F |
61 |
|
Adenocarcinoma |
n/a |
IV |
T2N1M1 |
F |
80 |
|
Adenocarcinoma |
n/a |
IIIA |
T3N0M0 |
F |
64 |
|
Adenocarcinoma |
2 |
II |
T2N0Mx |
F |
51 |
|
Adenocarcinoma |
2 |
IB |
T2N0Mx |
F |
56 |
|
Adenocarcinoma |
2 |
II |
T2N0Mx |
F |
63 |
|
Adenocarcinoma |
2 |
II |
T2N0Mx |
F |
66 |
|
Adenocarcinoma |
2 |
II |
T2N0Mx |
F |
53 |
|
Adenocarcinoma |
3 |
n/a |
n/a |
F |
70 |
|
Adenocarcinoma |
2 |
II |
T2N0Mx |
F |
32 |
|
Adenocarcinoma |
2 |
IB |
T2N0Mx |
F |
59 |
|
Large Cell Carcinoma |
n/a |
n/a |
n/a |
F |
45 |
|
Large Cell Carcinoma |
n/a |
n/a |
T2N0M0 |
F |
54 |
|
Large Cell Carcinoma |
n/a |
n/a |
T3N1Mx |
F |
60 |
|
Small Cell Carcinoma |
n/a |
II |
n/a |
F |
56 |
|
Spindle Cell Carcinoma |
n/a |
I |
T2N0M0 |
F |
25 |
|
Papillary Carcinoma |
1 |
IIIA |
T3N0M0 |
F |
41 |
References:
Travis WD, Colby TV, Corrin B, et al.: Histological typing of lung and pleural tumours. 3rd ed. Berlin: Springer-Verlag, 1999.
American Cancer Society.: Cancer Facts and Figures 2006. Atlanta, GA: American Cancer Society, 2006. Also available online. Last accessed May 20, 2006.